NasdaqGS - Nasdaq Real Time Price USD

Moderna, Inc. (MRNA)

122.69

+0.80

(+0.66%)

At close: May 9 at 4:00 PM EDT

123.48

+0.79

(+0.64%)

Pre-Market: 6:18 AM EDT

Moderna's Promise of mRNA Undercut by New RSV Vaccine

Moderna's second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Gerry Smith reports on Bloomberg Television.

Bloomberg 19 hours ago

MRNA
+0.66%
Sisk selected for MITC fit-out in Oxfordshire

The facility will provide domestic access to mRNA vaccines for Covid-19 and potentially other respiratory health threats.

World Construction Network 20 hours ago

MRNA
+0.66%
If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today

The COVID-19 pandemic thrust this company's science -- and its stock -- into the spotlight.

Motley Fool 21 hours ago

MRNA
+0.66%
Positive week for Moderna, Inc. (NASDAQ:MRNA) institutional investors who lost 6.8% over the past year

Key Insights Significantly high institutional ownership implies Moderna's stock price is sensitive to their trading...

Simply Wall St. 22 hours ago

MRNA
+0.66%
Moderna’s First Vaccine Was a Big Hit. Its Second Is a Let Down

(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t Track‘Seriously Underwater’ Home Mortgages Tick Up Across th

Bloomberg yesterday

MRNA
+0.66%
PFE
+1.18%
GSK
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?

Moderna stock broke out of a cup-with-handle base after its first-quarter sales and earnings report. Is MRNA stock a buy right now?

Investor's Business Daily yesterday

MRNA
+0.66%
Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna.

Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.

Barrons.com 5 days ago

VZ

MRNA
+0.66%
DIS
Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript

Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript May 2, 2024 Moderna, Inc. beats earnings expectations. Reported EPS is $-3.07, expectations were $-3.56. MRNA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing by. […]

Insider Monkey 5 days ago

MRNA
+0.66%
Analysts Are Updating Their Moderna, Inc. (NASDAQ:MRNA) Estimates After Its First-Quarter Results

Moderna, Inc. ( NASDAQ:MRNA ) just released its quarterly report and things are looking bullish. Revenues of US$167m...

Simply Wall St. 5 days ago

MRNA
+0.66%
Decoding Moderna Inc (MRNA): A Strategic SWOT Insight

Insightful Analysis of Moderna's Financial Health and Strategic Position

GuruFocus.com 6 days ago

MRNA
+0.66%
Moderna First Quarter 2024 Earnings: Beats Expectations

Moderna ( NASDAQ:MRNA ) First Quarter 2024 Results Key Financial Results Revenue: US$167.0m (down 91% from 1Q 2023...

Simply Wall St. 7 days ago

MRNA
+0.66%
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar

Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices. So, any company that develops a new drug to manage these ailments and obtain federal approval typically sees its stock price skyrocket. Three pharma stocks are for investors who are considering adding to their portfolios with this kind of potential. I believe that these firms repres

InvestorPlace 7 days ago

REGN

MRNA
+0.66%
VRTX
Moderna reports $1.2bn net loss in Q1 2024

Total revenue during the quarter saw a dramatic decrease to $167m from $1.9bn in the corresponding period of 2023.

Pharmaceutical Technology 7 days ago

MRNA
+0.66%
Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...

Despite a significant revenue drop, Moderna showcases robust clinical progress and strategic collaborations.

GuruFocus.com 7 days ago

MRNA
+0.66%
Why Moderna Stock Blasted 13% Higher Today

The company notched beats on both the top and bottom lines despite a major drop-off in demand for its famous product.

Motley Fool 7 days ago

MRNA
+0.66%
^GSPC
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year

The drugmaker is optimistic about higher sales with new vaccines and a little help from AI in the coming years.

Fortune 7 days ago

MRNA
+0.66%
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks

Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl

Yahoo Finance Video 7 days ago

NONOF

NVO

MRNA
+0.66%
Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views

Moderna stock broke out for the first time in a year Thursday after beating first-quarter expectations as its second potential approval looms.

Investor's Business Daily 7 days ago

MRNA
+0.66%
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars

Thursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an income of $(0.19), smaller than the consensus estimate loss of $(3.55). The company reported sales of $167 million, sharply below $1.9 billion a year ago due to evaporating COVID-19 vaccine sales, beating the consensus of $97.5 million. The company cut research and development expenses by 6% in the quarter, mainly due to the absence of upfront collaboration payments. Moderna added that clinical develop

Benzinga 7 days ago

MRNA
+0.66%
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration

After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma. Merck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockb

Benzinga 7 days ago

MRK

MRNA
+0.66%

Performance Overview

Return	MRNA	S&P 500
YTD	+23.37%	+9.31%
1-Year	-6.88%	+26.00%
3-Year	-24.80%	+23.19%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Moderna, Inc. (MRNA)

Moderna's Promise of mRNA Undercut by New RSV Vaccine

Sisk selected for MITC fit-out in Oxfordshire

If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today

Positive week for Moderna, Inc. (NASDAQ:MRNA) institutional investors who lost 6.8% over the past year

Moderna’s First Vaccine Was a Big Hit. Its Second Is a Let Down

Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?

Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna.

Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript

Analysts Are Updating Their Moderna, Inc. (NASDAQ:MRNA) Estimates After Its First-Quarter Results

Decoding Moderna Inc (MRNA): A Strategic SWOT Insight

Moderna First Quarter 2024 Earnings: Beats Expectations

Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar

Moderna reports $1.2bn net loss in Q1 2024

Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...

Why Moderna Stock Blasted 13% Higher Today

Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year

Novo Nordisk slides while Moderna pops: Tale of two pharma stocks

Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views

Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars

Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration

Performance Overview